AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

VENTURE LIFE GROUP PLC

Investor Presentation Feb 16, 2018

8004_rns_2018-02-16_962a934f-3bfa-4a9f-a106-f8046e3daac9.html

Investor Presentation

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0686F

Venture Life Group PLC

16 February 2018

Venture Life Group plc

("Venture Life" or the "Group")

Investor presentation

Venture Life Group (AIM: VLG), the international consumer self-care company focused on developing, manufacturing and commercialising products for the self-care market, is pleased to announce that Jerry Randall, CEO, will be presenting at an investor evening hosted by Turner Pope Investments ("TPI") Ltd.

TPI has been joint broker to Venture Life Group since September 2016. The event will be held on Monday 26 February in the City of London and will commence at 6pm. To Register your interest, please email [email protected] or call 0203 621 4120.

For further information please contact:

Venture Life Group PLC +44 (0) 1344 742870
Jerry Randall, Chief Executive Officer
Turner Pope Investments (TPI) Ltd (Joint Broker) +44 (0) 20 3621 4120
Rachel Evans

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising self-care products globally.  The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. 

The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its Development & Manufacturing business, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEAPASFAEPEFF

Talk to a Data Expert

Have a question? We'll get back to you promptly.